Furthermore, while SHIP2 has been implicated in obesity, diabetes and insulin resistance in rodents [52], [53] and in humans [45], [54], [55]; and has been suggested to have a proto-oncogenic role in human breast cancer [34], SHIP2 has not been associated with vascular disorders. This evidence concerns the gene INPPL1 and Insulin resistance.